New drug aims to stop swelling attacks in hereditary angioedema
NCT ID NCT06361537
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This phase 3 study tests an intravenous C1 esterase inhibitor (C1-INH) in people with hereditary angioedema (HAE) to treat acute attacks and prevent attacks before medical procedures. About 124 participants, aged 2 and older, will receive either the drug or a placebo. The main goal is to see how quickly symptoms like swelling improve.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
C1 esterase inhibitor (C1-INH) concentrate
What this could lead to
If successful, this could provide a fast-acting treatment and pre-procedure prevention for acute hereditary angioedema attacks, reducing swelling and pain.
What could go wrong
This is a phase 3 trial, but results may not confirm efficacy or safety for all patients. Risks include allergic reactions or lack of symptom relief.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA TYPE I are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Octapharma Research Site
RECRUITINGCentennial, Colorado, 80112, United States
-
Octapharma Research Site
WITHDRAWNFarmington Hills, Michigan, 48334, United States
-
Octapharma Research Site
WITHDRAWNToledo, Ohio, 43617, United States
-
Octapharma Research Site
WITHDRAWNTirana, Albania
-
Octapharma Research Site
RECRUITINGRosario, Argentina
-
Octapharma Research Site
RECRUITINGYerevan, Armenia
-
Octapharma Research Site
RECRUITINGSofia, 1431, Bulgaria
-
Octapharma Research Site
NOT_YET_RECRUITINGMexico City, 06720, Mexico
-
Octapharma Research Site
NOT_YET_RECRUITINGMéxico, Mexico
-
Octapharma Research Site
WITHDRAWNPodgorica, Montenegro
-
Octapharma Research Site
WITHDRAWNCluj-Napoca, 400162, Romania
-
Octapharma Research Site
WITHDRAWNKragujevac, 11221, Serbia
-
Octapharma Research Site
NOT_YET_RECRUITINGAnkara, Turkey (Türkiye)
-
Octapharma Research Site
NOT_YET_RECRUITINGIstanbul, Turkey (Türkiye)
-
Octapharma Research Site
WITHDRAWNIzmir, Turkey (Türkiye)
-
Octapharma Research Site
NOT_YET_RECRUITINGSakarya, Turkey (Türkiye)
-
Octapharma Research Site
RECRUITINGKyiv, 03057, Ukraine
-
Octapharma Research Site
WITHDRAWNLviv, 79010, Ukraine
-
Octapharma Research Site
NOT_YET_RECRUITINGLviv, 79035, Ukraine
-
Octapharma Research Site 5102
NOT_YET_RECRUITINGLima, 15001, Peru
-
Octapharma Research Site 5103
RECRUITINGLima, 15001, Peru